加替沙星
莫西沙星
医学
超声乳化术
抗生素
安慰剂
抗菌剂
外科
左氧氟沙星
化学
视力
替代医学
病理
生物化学
有机化学
作者
Frank A. Bucci,L.M. Amico,Ruth Evans
出处
期刊:Eye & Contact Lens-science and Clinical Practice
[Ovid Technologies (Wolters Kluwer)]
日期:2007-12-31
卷期号:34 (1): 39-42
被引量:23
标识
DOI:10.1097/icl.0b013e3180645d01
摘要
Purpose. To evaluate the ocular surface and aqueous antimicrobial effects of gatifloxacin and moxifloxacin administered in two dosing regimens to patients undergoing phacoemulsification. Methods. Patients were divided between two treatment groups and randomized to receive gatifloxacin 0.3% or moxifloxacin 0.5% within each group. Group 1 patients received antibiotics four times per day for 2 days before surgery with one additional drop the morning of surgery (n = 50, each drug). Group 2 patients were treated as in group 1, plus four drops (one drop every 10 minutes) during the hour before surgery (n = 60, each drug). Conjunctival and eyelid swabs were taken before surgery, and aqueous humor cultures were obtained immediately after surgery. Pathogens were identified and colony-forming units (CFUs) were counted. Results. No differences were observed between the antibiotics in mean CFUs in conjunctival cultures from group 1 (gatifloxacin, 59.9 ± 165.6 CFUs; moxifloxacin, 57.0 ± 214.7 CFUs; P=0.939) or group 2 (gatifloxacin, 76.7 ± 327.7 CFUs; moxifloxacin, 92.0 ± 486.1 CFUs; P=0.830). No differences were observed between antibiotics in mean CFUs in eyelid cultures from group 1 (gatifloxacin, 198.1 ± 330.1 CFUs; moxifloxacin, 168.3 ± 379.0; P=0.840) or group 2 (gatifloxacin, 556.8 ± 1,029.3 CFUs; moxifloxacin, 596.5 ± 1,013.5 CFUs; P=0.832). The overall rate of positive aqueous cultures in the 220 patients from groups 1 and 2 combined was less than 1% (i.e., no difference between antibiotics in either group). Conclusions. Preoperative topical ophthalmic gatifloxacin and moxifloxacin produced similar preoperative eyelid and conjunctival bacterial counts and identically low postsurgical aqueous contamination rates.
科研通智能强力驱动
Strongly Powered by AbleSci AI